Venous Thromboembolism Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation and Other Developments

The venous thromboembolism therapeutics pipeline is expected to witness considerable growth in the coming year due to the development of novel oral anticoagulants as a reasonable and established treatment option. The regulatory bodies are supporting the drug development process through different types of designations and funding. The pipeline is being driven by different factors such as increasing awareness regarding the venous thromboembolism therapeutics pipeline, high demand for safe, effective and affordable medications, technological advancements and increasing prevalence of the venous thromboembolism.

Explore Report at: www.psmarketresearch.com/market-analysis/venous-thromboembolism-therapeutics-pipeline-analysis

According to American Heart Association, Venous thromboembolism (VTE) collectively develops as a combination of deep vein thrombosis (DVT) and pulmonary embolism (PE), two life-threatening conditions. Venous thromboembolism is a common and preventable disease in which the clot formation occurs in the vein associated with Venous thromboembolism. In deep vein thrombosis, a clot formed in a deep vein, usually in the leg. Pulmonary embolism is a deep vein thrombosis clot that breaks free from a vein wall, travels to the lungs and blocks some or all of the blood supply. Blood clots in the thigh are more likely to break off and travel to the lungs than the clots in lower leg or other parts of the body.

Request for Table of Content at: www.psmarketresearch.com/market-analysis/venous-thromboembolism-therapeutics-pipeline-analysis/toc-sample

According to Centers for Disease Control and Prevention, the precise number of people affected by DVT/PE is unknown, although as many as 900,000 people could be affected (1 to 2 per 1,000) each year in the U.S. It is estimated that every year approximately, 60,000-100,000 Americans die of DVT/PE (also called venous thromboembolism). Around 10% to 30% of people die within one month of diagnosis. Approximately 5% to 8% of the U.S. population has one of several genetic risk factors, also known as inherited thrombophilia in which a genetic defect can be identified that increases the risk for thrombosis.

Browse Other Related Report at: www.psmarketresearch.com/industry-report/pharmaceuticals

Some of the companies having a pipeline of venous thromboembolism therapeutics include Bristol-Myers Squibb Company, Pfizer, Inc., Sanofi-Aventis, Daiichi Sankyo Co. Ltd., Astellas Pharma Inc. and Johnson & Johnson.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
Abhishek
Executive – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: www.psmarketresearch.com

347, 5th Ave. #1402
New York City, NY - 10016

This release was published on openPR.